A prospective stroke cohort associated preadmission benzodiazepine use with some poorer outcomes. The statistical conclusion depended partly on how baseline differences were handled.
The study recruited 370 acute ischemic-stroke patients, with 336 retained for the relevant comparison and sixty-two preadmission benzodiazepine users. Mortality, function, and cognitive screening were assessed at eight and ninety days.
The ninety-day mortality estimate remained significant in a propensity-adjusted analysis, but the matched analysis had a wide confidence interval crossing one. These analyses should be reported as distinct results rather than a single unqualified effect.
Benzodiazepine users may differ in illness, indication, frailty, and other characteristics. The authors identified indication bias, residual confounding, missing data, and limited power. Matching does not guarantee balance on unrecorded characteristics.
Cognitive assessment among survivors also addresses a selected subgroup, not everyone initially enrolled. No significant survivor-screening difference does not establish identical overall neurologic outcomes.
The paper does not support assuming neuroprotection from a drug’s receptor action. Equally, it cannot prove that preadmission medication caused an individual death. Explain the observational design, outcome time, analytic approach, and uncertainty before using it in causal testimony.
Original analysis of the supplied journal article, identified as PMC6340422.